These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25313252)

  • 41. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.
    Diel R; Loddenkemper R; Meywald-Walter K; Niemann S; Nienhaus A
    Am J Respir Crit Care Med; 2008 May; 177(10):1164-70. PubMed ID: 18276940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of QuantiFERON-TB Gold In-Tube Test and tuberculin skin test for identification of latent Mycobacterium tuberculosis infection in healthcare staff and association between positive test results and known risk factors for infection.
    Vinton P; Mihrshahi S; Johnson P; Jenkin GA; Jolley D; Biggs BA
    Infect Control Hosp Epidemiol; 2009 Mar; 30(3):215-21. PubMed ID: 19191484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States.
    Qumseya BJ; Ananthakrishnan AN; Skaros S; Bonner M; Issa M; Zadvornova Y; Naik A; Perera L; Binion DG
    Inflamm Bowel Dis; 2011 Jan; 17(1):77-83. PubMed ID: 20848501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients.
    Abreu C; Almeida F; Ferraz R; Dias CC; Sarmento A; Magro F
    Dig Liver Dis; 2016 Dec; 48(12):1438-1443. PubMed ID: 27599804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany.
    Diel R; Schaberg T; Loddenkemper R; Welte T; Nienhaus A
    Respir Med; 2009 Dec; 103(12):1838-53. PubMed ID: 19682884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. QuantiFERON-TB Gold In-Tube test for diagnosis of latent tuberculosis (TB) infection in solid organ transplant candidates: a single-center study in an area endemic for TB.
    Ahmadinejad Z; Azmoudeh Ardalan F; Razzaqi M; Davoudi S; Jafarian A
    Transpl Infect Dis; 2013 Feb; 15(1):90-5. PubMed ID: 23173720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
    Calzada-Hernández J; Anton-López J; Bou-Torrent R; Iglesias-Jiménez E; Ricart-Campos S; Martín de Carpi J; ; Torrente-Segarra V; Sánchez-Manubens J; Giménez-Roca C; Rozas-Quesada L; Juncosa-Morros MT; Fortuny C; Noguera-Julian A
    Pediatr Rheumatol Online J; 2015 Dec; 13():54. PubMed ID: 26635208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases.
    Soborg B; Ruhwald M; Hetland ML; Jacobsen S; Andersen AB; Milman N; Thomsen VO; Jensen DV; Koch A; Wohlfahrt J; Ravn P
    J Rheumatol; 2009 Sep; 36(9):1876-84. PubMed ID: 19648300
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries.
    Kowada A; Takasaki J; Kobayashi N
    J Hosp Infect; 2015 Feb; 89(2):99-108. PubMed ID: 25559158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
    Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
    Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy.
    Freund R; Granger B; Francois C; Carcelain G; Ravaud P; Mariette X; Fautrel B
    Presse Med; 2018 Feb; 47(2):e9-e13. PubMed ID: 29478790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children.
    Lucas M; Nicol P; McKinnon E; Whidborne R; Lucas A; Thambiran A; Burgner D; Waring J; French M
    Thorax; 2010 May; 65(5):442-8. PubMed ID: 20435869
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.
    Sellam J; Hamdi H; Roy C; Baron G; Lemann M; Puéchal X; Breban M; Berenbaum F; Humbert M; Weldingh K; Salmon D; Ravaud P; Emilie D; Mariette X;
    Ann Rheum Dis; 2007 Dec; 66(12):1610-5. PubMed ID: 17456528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis.
    Inanc N; Aydin SZ; Karakurt S; Atagunduz P; Yavuz S; Direskeneli H
    J Rheumatol; 2009 Dec; 36(12):2675-81. PubMed ID: 19918035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tuberculosis screening prior to anti-tumor necrosis factor therapy among patients with immune-mediated inflammatory diseases in Japan: a longitudinal study using a large-scale health insurance claims database.
    Tomio J; Yamana H; Matsui H; Yamashita H; Yoshiyama T; Yasunaga H
    Int J Rheum Dis; 2017 Nov; 20(11):1674-1683. PubMed ID: 29076252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Latent tuberculosis infection screening prior to biological treatment in Tunisian patients.
    Slouma M; Mahmoud I; Saidane O; Bouden S; Abdelmoula L
    Therapie; 2017 Oct; 72(5):573-578. PubMed ID: 28318613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis.
    Mullie GA; Schwartzman K; Zwerling A; N'Diaye DS
    BMC Med; 2017 May; 15(1):104. PubMed ID: 28514962
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents.
    Paluch-Oleś J; Magryś A; Kozioł-Montewka M; Koszarny A; Majdan M
    Arch Med Sci; 2013 Feb; 9(1):112-7. PubMed ID: 23515560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unaffected reaction level in tuberculin skin test by long-term therapy with tumor necrosis factor inhibitors for rheumatoid arthritis.
    Yamamoto S; Nagatani K; Sato T; Iwamoto M; Takatori S; Minota S
    Int J Rheum Dis; 2017 May; 20(5):584-588. PubMed ID: 28524434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.